| domain | key finding | quantitative detail | suggested ontology terms |
|---|---|---|---|
| Identity | APOB-related familial hypobetalipoproteinemia corresponds to FHBL1, a Mendelian low-LDL disorder caused primarily by APOB defects | MONDO:0014252; OMIM:615558; broader term hypobetalipoproteinemia MONDO:0017774 (pqac-00000001, pqac-00000013) | MONDO:0014252; MONDO:0017774 |
| APOB genetics and inheritance | APOB loss-of-function variants, especially truncating frameshift/nonsense/splice variants, impair apoB-containing lipoprotein formation; inheritance is autosomal codominant | >140 APOB variants reported; heterozygous disease common, biallelic disease extremely rare (pqac-00000001, pqac-00000011) | APOB; GO:0034379 very-low-density lipoprotein particle assembly; GO:0034380 chylomicron assembly |
| Heterozygous phenotype | Usually mild or asymptomatic, with moderate hypocholesterolemia and possible fatty liver | Estimated prevalence 1:1,000-1:3,000; severe steatohepatitis in ~5-10% (pqac-00000005, pqac-00000006, pqac-00000002) | HP:0003124 Hypocholesterolemia; HP:0001397 Hepatic steatosis |
| Biallelic phenotype | Severe multisystem disease resembling abetalipoproteinemia, driven by impaired intestinal and hepatic lipoprotein secretion | LDL-C and apoB may be absent/very low; prevalence/incidence <1 per million (pqac-00000005, pqac-00000006, pqac-00000010) | HP:0002595 Steatorrhea; HP:0001508 Failure to thrive; HP:0002153 Hyperbilirubinemia; HP:0001927 Acanthocytosis |
| Liver disease | Reduced VLDL export causes hepatic triglyceride retention and steatosis; progression can include steatohepatitis, fibrosis, rarely cirrhosis | Mean liver fat 14.8% ± 12.0 in FHBL vs 5.2% ± 5.9 controls; earlier study 16.7% ± 11.5 vs 3.3% ± 2.9 (pqac-00000003, pqac-00000006, pqac-00000007) | HP:0001397 Hepatic steatosis; HP:0002910 Elevated hepatic transaminases; UBERON:0002107 liver; GO:0006631 fatty acid metabolic process |
| Neurologic/ocular phenotypes | Untreated biallelic disease leads to fat-soluble vitamin deficiency with neuropathy, ataxia, retinal degeneration, night blindness, and visual field loss | Often begins in 1st-2nd decade if untreated; mortality may occur in 3rd decade without treatment (pqac-00000006, pqac-00000012) | HP:0001251 Ataxia; HP:0000608 Retinitis pigmentosa; HP:0000662 Nyctalopia; HP:0003431 Peripheral neuropathy |
| Diagnosis | Diagnosis relies on very low LDL-C/apoB plus APOB molecular testing; relatives with moderate hypolipidemia support FHBL1 over abetalipoproteinemia | Suggested severe thresholds: plasma LDL-C <15 mg/dL and/or apoB <15 mg/dL in homozygous disease; median diagnosis age 21 years in 2024 review (pqac-00000009, pqac-00000010) | HP:0003124 Hypocholesterolemia; HP:0010985 Abnormality of lipoprotein level; GO:0006869 lipid transport |
| Treatment | No disease-correcting therapy; management is dietary fat modification and high-dose fat-soluble vitamin supplementation with surveillance | Low-fat diet <30% calories; vitamin E 100-300 IU/kg/day, vitamin A 100-400 IU/kg/day, vitamin D 800-1200 IU/day, vitamin K 5-35 mg/week (pqac-00000005, pqac-00000008) | NCIT:C15604 Vitamin Therapy; CHEBI:33234 vitamin A; CHEBI:33238 vitamin D; CHEBI:33241 vitamin E; CHEBI:18067 vitamin K |
| Epidemiology and modifiers | Lifelong low LDL-C likely confers cardiovascular protection, but adiposity/insulin resistance can amplify liver fat burden; founder variants exist | In FHBL, intraperitoneal adipose tissue strongly predicted liver fat; in Lebanese families, APOB p.Arg490Trp accounted for 71% of probands (pqac-00000002, pqac-00000006, pqac-00000007) | HP:0003124 Hypocholesterolemia; HP:0001397 Hepatic steatosis |
| Models | Mouse and zebrafish models recapitulate impaired apoB secretion, fatty liver, and developmental consequences | ApoB-100 secretion reduced by ~80% rather than expected 50% in apoB-38.9 heterozygous mice; ApoB-null mice show embryonic lethality; zebrafish double mutants show intestinal defects and fatty liver (pqac-00000003, pqac-00000007) | GO:0034379 very-low-density lipoprotein particle assembly; GO:0034380 chylomicron assembly; CL:0000182 hepatocyte; CL:0000183 enterocyte; UBERON:0002107 liver; UBERON:0002108 small intestine |


*Table: This compact table summarizes the main disease-knowledge-base facts for APOB-related familial hypobetalipoproteinemia, including genetics, phenotypes, diagnostics, treatment, epidemiology, and model systems. It also suggests ontology terms useful for structured annotation.*